Antibody
- +1 609-736-0910
- [email protected]
- 90 State Street, STE 700 Office 40, Albany, NY 12207 United States
Product Background
Catalog Number |
ADT1171 |
Product Name |
High-Quality Dezamizumab Biosimilar: Anti-APCS mab-Research Grade |
Tags |
biosimilar antibodies, biosimilar monoclonal antibodies, apcs protein, anti apcs antibody, Dezamizumab Biosimilar, Dezamizumab, APCS, 1662664-56-3 |
CAS Number |
1662664-56-3 |
Target |
APCS[Homo sapiens] |
Alias |
GSK-2398852 |
Clonity |
Monoclonal |
Isotype |
IgG1 Kappa |
Host |
CHO Cells |
Research area |
Immunology |
Application |
ELISA, IHC, IF, IP, Flow Cyt, FuncS |
Size |
100ug,1mg,5mg |
Concentration |
batch dependent |
Buffer |
Supplied in PBS, PH7.5 |
Purity |
>95% as determined by SDS-PAGE |
Storage |
Store at -20 °C for 12 months. Store at -80 °C for long term storage. Avoid repeated freezing and thawing. |
Shipping Condition |
Shipped on ice packs. |
Note |
This product is for research use only. |
FAQ
-
+ -
What are the potential benefits of biosimilars ?
Biosimilars provide more affordable alternatives to reference biologic drugs. By introducing competition into the market, biosimilars can help reduce healthcare costs, making treatment more accessible and potentially expanding patient access to critical therapies. It's important to note that the benefits of biosimilars may vary depending on the specific healthcare system, regulatory environment, and individual circumstances. Additionally, the introduction and adoption of biosimilars should be supported by robust regulatory frameworks, rigorous clinical and analytical assessments, and ongoing pharmacovigilance to ensure patient safety and confidence in these therapies.
-
+ -
How are biosimilar manufactured?
The manufacturing process begins with the selection and development of a suitable host cell line for protein expression. Once the cell line is established, large-scale fermentation is conducted to produce the recombinant protein. After the fermentation process is complete, the culture broth containing the expressed protein is harvested from the bioreactor.The harvested protein undergoes purification to isolate the desired product from other cellular components and contaminants. Once purified, the protein is formulated into a final dosage form suitable for administration to patients. Throughout the manufacturing process, rigorous quality control testing is conducted to assess the identity, purity, potency, and safety of the biosimilar product. Upon completion of manufacturing and quality control testing, each batch of biosimilar product undergoes final review and approval by regulatory authorities before it can be released for distribution and use in clinical practice.
-
+ -
What is the difference between a biosimilar and generic?
Biosimilars are biological products that are highly similar to an already approved reference biological product, whereas generics are chemically identical copies of small molecule drugs.
Biosimilars are manufactured using living organisms, such as bacteria or mammalian cells, through recombinant DNA technology. The manufacturing process for biosimilars involves complex biological processes and requires meticulous control to ensure consistency and quality. In contrast, generics are manufactured through chemical synthesis, which typically involves simpler and more standardized processes.
-
+ -
Do biosimilars have the same side effects and safety profile as the reference products?
Biosimilars are required to demonstrate comparable safety profiles to their reference products through extensive preclinical and clinical studies. Adverse events associated with biosimilars are typically consistent with those observed with the reference products and are closely monitored during clinical trials and post-marketing surveillance. However, individual patient responses may vary, and healthcare professionals should remain vigilant for any unexpected adverse reactions when transitioning between products.